THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [4.9] ID: TIP-MED-000053

Dapagliflozin Propanediol Monohydrate

Active Ingredient / Scientific Identity: Dapagliflozin Propanediol Monohydrate • Class: Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor (Gliflozin); Cardiorenal Protective Agent

⚖️ Compare Profile
Generic / Entity NameDapagliflozin Propanediol Monohydrate ([4.9])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassSodium-Glucose Cotransporter-2 (SGLT2) Inhibitor (Gliflozin); Cardiorenal Protective Agent
Available Dosage FormsOral Film-Coated Tablets: 5 mg, 10 mg
Regulatory ClassificationSchedule H Prescription Drug • CDSCO Approved (T2DM, HFrEF/HFpEF, CKD)
Key Warning & Review DateIn severe hepatic impairment (Child-Pugh C), start at 5 mg once daily and increase to 10 mg if tolerated.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug • CDSCO Approved (T2DM,✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Dapagliflozin Propanediol Monohydrate (TIP-MED-000053, Reference Code [4.9]) is classified under Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04) as a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor (Gliflozin); Cardiorenal Protective Agent. Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug • CDSCO Approved (T2DM, HFrEF/HFpEF, CKD).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.9], p. 49): Forxiga (AstraZeneca), Oxra (Sun Pharma), Udapa (Lupin), Gledepa, Dapamac (Macleods), Dapanorm (Alkem); In FDC with Metformin: Xigduo-XR, Oxramet; In FDC with Sitagliptin: Sidapvia / Oxra-S — Strengths & Forms: Oral Film-Coated Tablets: 5 mg, 10 mg
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.9], p. 49): Forxiga (AstraZeneca), Oxra (Sun Pharma), Udapa (Lupin), Gledepa, Dapamac (Macleods), Dapanorm (Alkem); In FDC with Metformin: Xigduo-XR, Oxramet; In FDC with Sitagliptin: Sidapvia / Oxra-S — Strengths & Forms: Oral Film-Coated Tablets: 5 mg, 10 mg
Dosage Forms & Available Strengths:
Oral Film-Coated Tablets: 5 mg, 10 mg
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Selectively and reversibly inhibits Sodium-Glucose Cotransporter-2 (SGLT2) in the S1 segment of the renal proximal convoluted tubule (PCT), which normally reabsorbs 90% of filtered glucose. Produces insulin-independent urinary glucose excretion (~70 g/day = ~280 kcal/day) and natriuresis, restoring tubuloglomerular feedback (afferent arteriolar constriction) and reducing intraglomerular hypertension.

4. Therapeutic Indications & Evidence-Supported Uses

  • Type 2 Diabetes Mellitus (glycaemic control & CV event reduction)
  • Heart Failure across the full ejection fraction spectrum (HFrEF & HFpEF — with or without diabetes)
  • Chronic Kidney Disease (CKD) to slow eGFR decline and reduce ESKD/CV death

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adults (T2DM, Heart Failure, or CKD): 10 mg orally once daily at any time of day.

Administration & Meal Timing: Oral; once daily with or without food.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
In severe hepatic impairment (Child-Pugh C), start at 5 mg once daily and increase to 10 mg if tolerated.
Elimination & Renal Adjustment:
For glycaemic lowering alone, efficacy declines when eGFR < 45 mL/min; however, for Heart Failure and CKD renoprotection, 10 mg/day may be initiated down to eGFR >= 25 mL/min and continued until dialysis.
Hepatic Impairment Considerations:
In severe hepatic impairment (Child-Pugh C), start at 5 mg once daily and increase to 10 mg if tolerated.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Type 1 Diabetes Mellitus (high risk of euglycaemic DKA)
  • Patients on dialysis
  • Pregnancy and lactation

Key Clinical Precautions: In severe hepatic impairment (Child-Pugh C), start at 5 mg once daily and increase to 10 mg if tolerated.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Genital mycotic infections (vulvovaginal candidiasis, balanitis — 5%–8% due to glycosuria) and urinary tract infections
  • Euglycaemic Diabetic Ketoacidosis (euDKA — blood glucose may be <250 mg/dL during surgery, fasting, or acute illness)
  • Volume depletion, postural hypotension, and transient initial haemodynamic eGFR dip (3–5 mL/min)
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Loop Diuretics (Furosemide): additive osmotic diuresis and volume depletion / orthostatic hypotension
  • Insulin or Sulfonylureas (Glimepiride): reduce insulin/SU dose by 10–20% to prevent hypoglycaemia
  • Lithium: SGLT2 inhibitors increase renal lithium clearance and may decrease serum lithium levels

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Hold Dapagliflozin at least 3 days before major scheduled surgery or during acute febrile dehydrating illness ('Sick-Day Rule') to prevent euglycaemic ketoacidosis.
  • Maintain good perineal hygiene and adequate oral hydration to prevent genital fungal infections.
  • Seek immediate medical care if nausea, vomiting, abdominal pain, or fruity breath develops even if blood glucose appears normal.

Storage, Stability & Dispensing Safeguards: Store below 30°C.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2026) • NLEM 2022 (MoHFW) • CDSCO Approved Prescribing Information

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.